Novocure Stock Plunges After Phase 3 TRIDENT Study Fails to Meet Primary Goal
Novocure’s Phase 3 TRIDENT trial failed to show survival benefit from earlier TTFields initiation in newly diagnosed glioblastoma.
/ 3 items
#NVCR↓
NovoCure’s Medicare Scare Lasts Just 22 Days — Billing Fully Restored, No Revenue Hit
NovoCure’s (NVCR) Medicare billing privileges were briefly revoked due to a paperwork glitch but fully restored retroactively on Feb 24, 2026. Patients continued care with zero expected revenue impact.
FDA Approves Novocure's Optune Pax: A New Hope for Pancreatic Cancer Patients
Novocure's Optune Pax wearable device wins FDA approval for locally advanced pancreatic cancer with gemcitabine + nab-paclitaxel. Phase 3 trial shows improved survival and delayed pain progression.